Overview

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)
Treatments:
Dolastatin 10